Skip to main content
. Author manuscript; available in PMC: 2010 Jul 20.
Published in final edited form as: Brain Behav Immun. 2006 Jan;20(1):57–63. doi: 10.1016/j.bbi.2005.02.003

Fig. 3.

Fig. 3

Increasing the dose of IGF-I attenuates IL-1β-induced sickness behavior. SAL or IGF-I (.1 or 1 μg) was injected i.c.v. just before SAL or IL-1 injected via the same route. The figure represents duration of social exploration (A) and immobility (B) measured immediately before the treatments and at various time intervals thereafter. [(A): **p < .01 for SAL-IL-1 vs IGF (.1)-IL-1 and *p < .05 for SAL-IL-1 vs IGF (1)-IL-1; (B): **p < .01 for SAL-IL-1 vs both IGF (.1)-IL-1 and IGF (1)-IL-1]. Values are means ± SEM.